Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia

Blood Cancer United has announced the acquisition of the remaining supply of luveltamab tazevibulin, a promising investigational therapy for children suffering from a rare and aggressive form of acute myeloid leukemia (AML). The deal, finalized on June 11, 2026, involves an undisclosed amount and is aimed at ensuring continued access to this treatment for pediatric patients facing a daunting survival rate of only 15% to 30%. This acquisition allows the drug to be made available at no cost to eligible patients through the FDA's compassionate use pathway.

Luveltamab tazevibulin is an antibody-drug conjugate that targets the Folate Receptor-1 (FOLR1) and has shown early promise for a subtype of AML known as CBFA2T3-GLIS2-rearranged AML. This specific subtype is diagnosed in approximately 17 children annually in the United States and is known for its resistance to conventional chemotherapy. The discontinuation of a compassionate use program for this drug left many families with limited options, prompting Blood Cancer United to step in and acquire the existing supply and rights to facilitate its continued use.

The strategic rationale behind this acquisition is rooted in the challenges faced by families dealing with rare diseases. Blood Cancer United aims to preserve access to effective treatments while advocating for clearer regulatory pathways and shared trial infrastructures that could facilitate further research and development of therapies for pediatric cancers. E. Anders Kolb, M.D., president and CEO of Blood Cancer United, highlighted the importance of maintaining access to promising therapies, particularly in light of the operational hurdles and commercial calculations that often hinder the availability of such treatments.

This intervention is not only critical for families like that of Aspen Peck, a young patient who benefited from luveltamab tazevibulin, but also underscores the broader challenges within the pediatric oncology landscape. With limited data available for rare diseases, the acquisition of this drug represents a vital lifeline for children who have few treatment options. The ongoing commitment of Blood Cancer United to pediatric cancer research, supported by significant funding and partnerships, reflects a proactive approach to addressing these urgent medical needs.

The acquisition of luveltamab tazevibulin by Blood Cancer United signals a significant step forward in the nonprofit healthcare sector's ability to respond to the needs of vulnerable patient populations. As the organization continues to advocate for improved access to innovative therapies, the implications of this deal may resonate throughout the industry, potentially influencing future regulatory approaches and funding strategies for rare pediatric diseases. The success of this initiative could pave the way for similar interventions, ultimately enhancing treatment options for children facing life-threatening conditions.